☰

Emma Ito, Ph.D. - Publications

Affiliations: 
2010 Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Oncology, Medical Biophysics
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Cheung R, Ito E, Lopez M, Rubinstein E, Keller H, Cheung F, Liu ZA, Liu FF, Wong P. Evaluating the Short-Term Environmental and Clinical Effects of a Radiation Oncology Department's Response to the COVID-19 Pandemic (STEER COVID-19). International Journal of Radiation Oncology, Biology, Physics. PMID 36309074 DOI: 10.1016/j.ijrobp.2022.04.054  0.374
2021 Harnett N, Tosoni S, Brandt C, Ito E, Milne E, Liu FF, Wong R. Accelerated Education Program in Radiation Medicine: International Learner Perceptions of Experiences, Outcomes, and Impact. International Journal of Radiation Oncology, Biology, Physics. 109: 656-660. PMID 33516435 DOI: 10.1016/j.ijrobp.2020.09.051  0.368
2020 Ito E, Moraes FY, Ramotar M, Lunsky I, Soliman H, Catton CN, Kassam Z, Morton G, Tosoni S, Gospodarowicz M, Wong RKS, Liu FF, Chung PWM. Radiation Oncology Fellowship: a Value-Based Assessment Among Graduates of a Mature Program. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. PMID 32683629 DOI: 10.1007/S13187-020-01767-5  0.371
2015 Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal Cancer: Molecular Landscape. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26351340 DOI: 10.1200/Jco.2015.60.7846  0.612
2014 Williams JP, Kim I, Ito E, Shi W, Yue S, Siu LL, Waldron J, O'Sullivan B, Yip KW, Liu FF. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. Plos One. 9: e98557. PMID 24853121 DOI: 10.1371/Journal.Pone.0098557  0.547
2013 Lenarduzzi M, Hui AB, Yue S, Ito E, Shi W, Williams J, Bruce J, Sakemura-Nakatsugawa N, Xu W, Schimmer A, Liu FF. Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. Plos One. 8: e74075. PMID 23991213 DOI: 10.1371/Journal.Pone.0074075  0.688
2013 Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment Bmc Proceedings. 7. DOI: 10.1186/1753-6561-7-S2-P19  0.557
2012 P'ng C, Ito E, How C, Bezjak A, Bristow R, Catton P, Fyles A, Gospodarowicz M, Jaffray D, Kelley S, Wong S, Liu FF. Excellence in Radiation Research for the 21st Century (EIRR21): description of an innovative research training program. International Journal of Radiation Oncology, Biology, Physics. 83: e563-70. PMID 22520480 DOI: 10.1016/J.Ijrobp.2012.02.035  0.593
2012 Williams JP, Kim I, Yue S, Shi W, Ito E, Siu LL, Waldron J, Liu F. Abstract 2879: Pre-clinical characterization of Dacomitinib, an irreversible pan-HER inhibitor, combined with radiation therapy in head and neck cancer models Cancer Research. 72: 2879-2879. DOI: 10.1158/1538-7445.Am2012-2879  0.531
2011 Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. Bmc Cancer. 11: 500. PMID 22128797 DOI: 10.1186/1471-2407-11-500  0.709
2011 Ito E, Yip KW, Liu FF. Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer. Future Oncology (London, England). 7: 595-7. PMID 21568673 DOI: 10.2217/Fon.11.27  0.493
2011 Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B, Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Research. 71: 2381-91. PMID 21385904 DOI: 10.1158/0008-5472.Can-10-2754  0.705
2011 Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Science Translational Medicine. 3: 67ra7. PMID 21270338 DOI: 10.1126/Scitranslmed.3001922  0.584
2010 Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu FF. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death & Disease. 1: e85. PMID 21368858 DOI: 10.1038/Cddis.2010.64  0.701
2010 Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. European Journal of Cancer (Oxford, England : 1990). 46: 1967-78. PMID 20451372 DOI: 10.1016/J.Ejca.2010.04.004  0.515
2010 Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics. 77: 253-60. PMID 20394857 DOI: 10.1016/J.Ijrobp.2009.11.027  0.525
2010 Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, Chan N, Bhogal N, Coackley CL, Vines D, Green D, Waldron J, Gullane P, Bristow R, Liu FF. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 898-911. PMID 20103674 DOI: 10.1158/1078-0432.Ccr-09-1945  0.535
2010 Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, Busson P, Lo KW, Ng R, Waldron J, O'Sullivan B, Liu FF. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. International Journal of Cancer. Journal International Du Cancer. 126: 2036-48. PMID 19739117 DOI: 10.1002/Ijc.24880  0.619
2010 Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Abstract SSY01-03: An RNAi screen identifies a heme biosynthetic mediator as a novel radiosensitizing target for head and neck cancer Tumor Biology. DOI: 10.1158/1538-7445.Am10-Ssy01-03  0.506
2009 Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu FF. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Molecular Pharmacology. 76: 969-83. PMID 19654225 DOI: 10.1124/Mol.109.055277  0.524
2009 Hui AB, Yue S, Shi W, Alajez NM, Ito E, Green SR, Frame S, O'Sullivan B, Liu FF. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3716-24. PMID 19470731 DOI: 10.1158/1078-0432.Ccr-08-2790  0.506
2009 Katz D, Ito E, Liu FF. On the path to seeking novel radiosensitizers. International Journal of Radiation Oncology, Biology, Physics. 73: 988-96. PMID 19251086 DOI: 10.1016/J.Ijrobp.2008.12.002  0.487
2008 Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF. Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. Biotechniques. 44: ix-xiv. PMID 18422490 DOI: 10.2144/000112757  0.485
2006 Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Molecular Cancer Therapeutics. 5: 2234-40. PMID 16985057 DOI: 10.1158/1535-7163.Mct-06-0134  0.501
Show low-probability matches.